HOOKIPA Pharma Inc.

NasdaqCM:HOOK Stock Report

Market Cap: US$14.9m

HOOKIPA Pharma Past Earnings Performance

Past criteria checks 0/6

HOOKIPA Pharma's earnings have been declining at an average annual rate of -3.8%, while the Biotechs industry saw earnings growing at 23.5% annually. Revenues have been growing at an average rate of 26% per year.

Key information

-3.8%

Earnings growth rate

27.9%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate26.0%
Return on equity-84.9%
Net Margin-99.0%
Last Earnings Update31 Dec 2024

Recent past performance updates

Recent updates

The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 26%

Dec 21
The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 26%

Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky

Nov 19
Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky

HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues

Sep 27
HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues

The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 29%

Aug 13
The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 29%

Why Investors Shouldn't Be Surprised By HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 34% Share Price Plunge

Jun 22
Why Investors Shouldn't Be Surprised By HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 34% Share Price Plunge

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth

Apr 28
HOOKIPA Pharma Inc. (NASDAQ:HOOK) Shares Fly 25% But Investors Aren't Buying For Growth

Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts

Mar 24
Analysts Just Made A Major Revision To Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenue Forecasts

Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023

Aug 11
Need To Know: The Consensus Just Cut Its HOOKIPA Pharma Inc. (NASDAQ:HOOK) Estimates For 2023

HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%

May 16
HOOKIPA Pharma Inc. (NASDAQ:HOOK) Analysts Just Slashed This Year's Revenue Estimates By 17%

Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

Apr 26
Is HOOKIPA Pharma (NASDAQ:HOOK) A Risky Investment?

Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues

Nov 19
Need To Know: Analysts Are Much More Bullish On HOOKIPA Pharma Inc. (NASDAQ:HOOK) Revenues

HOOKIPA wins FDA nod to start clinical studies for prostate cancer therapy

Jul 25

Revenue & Expenses Breakdown

How HOOKIPA Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:HOOK Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2444-44220
30 Sep 2450-43200
30 Jun 2452-49190
31 Mar 2454-48190
31 Dec 2320-82200
30 Sep 2321-69200
30 Jun 2316-682040
31 Mar 2316-67200
31 Dec 2214-65200
30 Sep 2210-74200
30 Jun 2212-76200
31 Mar 2215-76200
31 Dec 2118-76190
30 Sep 2120-67210
30 Jun 2120-60210
31 Mar 2121-50200
31 Dec 2020-44200
30 Sep 2018-42190
30 Jun 2016-40190
31 Mar 2013-45190
31 Dec 1912-43170
30 Sep 1913-35140
30 Jun 1913-27100
31 Mar 1910-2180
31 Dec 188-1670

Quality Earnings: HOOK is currently unprofitable.

Growing Profit Margin: HOOK is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: HOOK is unprofitable, and losses have increased over the past 5 years at a rate of 3.8% per year.

Accelerating Growth: Unable to compare HOOK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HOOK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (40.2%).


Return on Equity

High ROE: HOOK has a negative Return on Equity (-84.94%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/18 22:05
End of Day Share Price 2025/03/18 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

HOOKIPA Pharma Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
Yu HeH.C. Wainwright & Co.
Swayampakula RamakanthH.C. Wainwright & Co.